LC Virtual Symposium


Please join us for the 2022 DF/HCC Lung Cancer Program’s Annual Symposium.


Neoadjuvant Immunotherapy in the Treatment of Early-Stage Lung Cancer


DOWNLOAD THE AGENDA 

8:00-8:30am

Continental Breakfast

 

8:30-8:40am

Introduction: Bruce Johnson, MD, Dana-Farber Cancer Institute

Morning Session Chair: Lecia Sequist, MD

8:40-9:20am

Surgical Resection following Immunotherapy for Early- Stage Lung Cancer

Q&A

Michael Lanuti, MD
Director, Thoracic Oncology, Division of Thoracic Surgery
Associate Professor Harvard Medical School
Friedman-Lambert Scholar in Academic Thoracic Surgery


9:20-10:00am

Segmentectomy versus Lobectomy for Early- Stage Lung Cancer

Q&A

Nasser Altorki, MD
David B. Skinner, M.D. Professor of Thoracic Surgery, Cardiothoracic Surgery, Weill Cornell Medical College

 

10:00-11:10am

Morning Poster Session

Grand Ballroom Lobby and Hallway

11:10-11:25am

Complete anatomic segmentectomy shows improved oncologic outcomes compared to incomplete anatomic segmentectomy

Miles McAllister
Research Assistant, Brigham and Women’s Hospital

11:25-11:40am

Genomic and immunophenotypic correlates of recurrence and disease-free survival after surgically-resected stage I non-small cell lung cancer (NSCLC).

 

Joao Alessi, MD
Clinical Research Scientist II
Dana-Farber Cancer Institute

11:40-12:20am

Mechanisms of Response and Resistance to Immunotherapies in Early-Stage Lung Cancer

Q &A

Tina Cascone, MD, PhD
Assistant Professor, Thoracic and Head and Neck Cancer, Department of Medicine
MD Anderson Cancer Center

12:20-1:10pm

Lunch

 

 

Afternoon Session Chair: Daniel Costa, MD, PhD

1:10-1:50pm

Personalizing perioperative systemic therapy in early-stage lung cancer

Mark Awad, MD, PhD
Director of Clinical Research, Thoracic Oncology, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School

1:50-2:05pm

GUK1 is a novel metabolic liability in ALK+ lung cancer

Jaime Schneider, MD, PhD
Assistant in Medicine, Massachusetts General Hospital
Instructor in Medicine, Harvard Medical School

2:05-2:20pm

PRKRA is a preferential genetic dependency in neuroendocrine lung cancer cells

Tao Zou, MD, PhD
Instructor in Medicine
Dana-Farber Cancer Institute

2:20-3:00pm

Minimally Invasive Surgery for Early-Stage Lung Cancer

Q&A

Paula Antonia Ugalde Figueroa, MD
Associate Surgeon, Division of Thoracic Surgery Department of Surgery, Brigham and Women’s Hospital

 

3:00-4:10 pm 

Afternoon Poster Session and Break

 


4:10-4:40 pm

 

Panel:
Management of Early-Stage Lung Cancer

Scott Swanson, MD
Canepari Family Distinguished Chair in Thoracic Surgery
Associate Chief of Surgery, Dana-Farber Cancer Institute
Professor of Surgery, Harvard Medical School

 

 

Panel:
Management of Early-Stage Lung Cancer

Michael Lanuti, MD
Director, Thoracic Oncology, Division of Thoracic Surgery
Associate Professor Harvard Medical School
Friedman-Lambert Scholar in Academic Thoracic Surgery 

 

Panel:
Management of Early-Stage Lung Cancer

Mark Awad, MD, PhD
Director of Clinical Research, Thoracic Oncology, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School

 

Panel:
Management of Early-Stage Lung Cancer

Florence (Katie) Keane, MD
Assistant Professor in Radiation Oncology, Harvard Medical School

 

 

Panel:
Management of Early-Stage Lung Cancer

Paula Antonia Ugalde Figueroa, MD
Associate Surgeon, Division of Thoracic Surgery Department of Surgery, Brigham and Women’s Hospital

The End

  


POSTER DISCUSSANTS


David Christiani, MD, MPH
Harvard T.H. Chan School of Public Health
Carla Kim, PhD
Boston Children’s Hospital
Justin Gainor, MD,
Massachusetts General Hospital
Daniel Costa, MD, PhD
Dana-Farber Cancer Institute
Bruce Johnson, MD
Dana-Farber Cancer Institute
Lecia Sequist, MD, MPH 
Massachusetts General Hospital

Chi-Fu Jeffrey Yang, MD
Massachusetts General Hospital